{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:32:41Z","timestamp":1786354361280,"version":"build-2736575974"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"American Society of Clinical Oncology Career Development"},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA090628"],"award-info":[{"award-number":["K12CA090628"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA116201"],"award-info":[{"award-number":["P50 CA116201"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA077598"],"award-info":[{"award-number":["P30CA077598"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35CA253187"],"award-info":[{"award-number":["R35CA253187"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA225662"],"award-info":[{"award-number":["R01CA225662"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Breast Cancer Resource Foundation"},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-2-0025"],"award-info":[{"award-number":["W81XWH-22-2-0025"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BRCA Research and Cure Alliance"},{"name":"Susan G. Komen Foundation","award":["SAC210105"],"award-info":[{"award-number":["SAC210105"]}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["PF-23 to 1153194-01-CDP"],"award-info":[{"award-number":["PF-23 to 1153194-01-CDP"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The association of germline pathogenic and likely pathogenic variants (GPVs) in hereditary breast cancer genes with underlying tumor biology and clinical outcomes remains incompletely understood. This study characterized differences in somatic alterations and intrinsic subtypes between sporadic and hereditary breast cancers associated with GPVs in ATM, BRCA1, BRCA2, CHEK2, or PALB2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included women with breast cancer and an ATM, BRCA1, BRCA2, CHEK2, or PALB2 GPV who had undergone tumor sequencing and whole transcriptome RNA expression analysis. Clinicopathological features, intrinsic subtypes, somatic alterations, and survival were compared by GPV status and immunohistochemistry-defined subtype and to sporadic cases. All statistical significance tests were 2-sided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 4988 women with breast cancer in this study included 98 BRCA1, 126 BRCA2, 74 PALB2, 54 ATM, and 83 CHEK2 GPVs. Compared with sporadic cases, hormone receptor\u2013positive\/(ERBB2) formerly HER2\u2013negative tumors in BRCA1 GPVs were statistically significantly enriched for basal subtype (45.5% vs 11.4%; P\u2009&amp;lt;\u2009.001), while CHEK2 carriers had a higher prevalence of luminal A subtype (80.4% vs 60.3%; P\u2009=\u2009.006). In hormone receptor\u2013positive\/(ERBB2)-negative breast cancers, BRCA1 GPVs were enriched for TP53 alterations (84.6% vs 29.8%; q\u2009&amp;lt;\u20090.001), ATM GPVs with FGFR1 alterations (35.4% vs 12.7%; q\u2009=\u20090.04), and BRCA2 GPVs with APC alterations (10.1% vs 1.5%; q\u2009=\u20090.004). Conversely, BRCA2 GPVs were inversely associated with PIK3CA alterations (13.0% vs 34.1%; q\u2009=\u20090.005) and CHEK2 GPVs with TP53 alterations (8.0% vs 29.8%; q\u2009=\u20090.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The GPVs in BRCA1, BRCA2, ATM, CHEK2, and PALB2 are associated with distinct intrinsic breast cancer subtypes and somatic genomic alterations. These findings may enhance precision in risk stratification and guide personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag070","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:06:32Z","timestamp":1773234392000},"page":"1416-1424","source":"Crossref","is-referenced-by-count":0,"title":["Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-9903","authenticated-orcid":false,"given":"Siddhartha","family":"Yadav","sequence":"first","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-5233","authenticated-orcid":false,"given":"Sonya","family":"Reid","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Vanderbilt University Medical Center , Nashville, TN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8845-5390","authenticated-orcid":false,"given":"Binyam","family":"Yilma","sequence":"additional","affiliation":[{"name":"Tempus AI , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatina","family":"Fragkogianni","sequence":"additional","affiliation":[{"name":"Tempus AI , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3435-2464","authenticated-orcid":false,"given":"Jennifer G","family":"Whisenant","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Vanderbilt University Medical Center , Nashville, TN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-8734","authenticated-orcid":false,"given":"Anne","family":"Weidner","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Vanderbilt University Medical Center , Nashville, TN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-0819","authenticated-orcid":false,"given":"Padma Sheila","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"National Cancer Institute Cancer Data Science Laboratory, , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Tempus AI , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8033-0696","authenticated-orcid":false,"given":"Elizabeth","family":"Mauer","sequence":"additional","affiliation":[{"name":"Tempus AI , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-3039","authenticated-orcid":false,"given":"Ali T","family":"Arafa","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Chao","sequence":"additional","affiliation":[{"name":"Tempus AI , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5506-1749","authenticated-orcid":false,"given":"Emily A","family":"Teslow","sequence":"additional","affiliation":[{"name":"Tempus AI , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-3851","authenticated-orcid":false,"given":"Emmanuel S","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-9470","authenticated-orcid":false,"given":"Allison","family":"Kurian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine , Stanford, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-9985","authenticated-orcid":false,"given":"Fergus J","family":"Couch","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-2475","authenticated-orcid":false,"given":"Tuya","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center , Nashville, TN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"2026081005033030800_djag070-B1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041318","article-title":"Germline genetic testing for hereditary breast and ovarian cancer: current concepts in risk evaluation","volume":"14","author":"Yadav","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026081005033030800_djag070-B2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081005033030800_djag070-B3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2026081005033030800_djag070-B4","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026081005033030800_djag070-B5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-012-2348-2","article-title":"Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer","volume":"137","author":"Rummel","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2026081005033030800_djag070-B6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","article-title":"Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis","volume":"16","author":"Cybulski","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026081005033030800_djag070-B7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N Engl J Med"},{"key":"2026081005033030800_djag070-B8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/EDBK_238987","article-title":"Germline genetic testing for breast cancer risk: the past, present, and future","volume":"39","author":"Yadav","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026081005033030800_djag070-B9","doi-asserted-by":"crossref","first-page":"e216744","DOI":"10.1001\/jamaoncol.2021.6744","article-title":"Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes","volume":"8","author":"Mavaddat","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026081005033030800_djag070-B10","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026081005033030800_djag070-B11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41523-021-00224-w","article-title":"Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants","volume":"7","author":"Lambertini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2026081005033030800_djag070-B12","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026081005033030800_djag070-B13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4137\/BCBCR.S18715","article-title":"Hereditary breast cancer: clinical, pathological and molecular characteristics","volume":"8","author":"Larsen","year":"2014","journal-title":"Breast Cancer (Auckl)"},{"key":"2026081005033030800_djag070-B14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrclinonc.2011.178","article-title":"Practical implications of gene-expression-based assays for breast oncologists","volume":"9","author":"Prat","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2026081005033030800_djag070-B15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"2026081005033030800_djag070-B16","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1634\/theoncologist.2014-0372","article-title":"Defining breast cancer intrinsic subtypes by quantitative receptor expression","volume":"20","author":"Cheang","year":"2015","journal-title":"Oncologist"},{"key":"2026081005033030800_djag070-B17","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1093\/emboj\/20.17.4704","article-title":"Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences","volume":"20","author":"Tutt","year":"2001","journal-title":"Embo J"},{"key":"2026081005033030800_djag070-B18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2026081005033030800_djag070-B19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2026081005033030800_djag070-B20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2026081005033030800_djag070-B21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"2026081005033030800_djag070-B22","doi-asserted-by":"crossref","first-page":"16142","DOI":"10.1002\/cam4.6272","article-title":"Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival","volume":"12","author":"Morra","year":"2023","journal-title":"Cancer Med"},{"key":"2026081005033030800_djag070-B23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ijc.34304","article-title":"Survival outcomes of metastatic breast cancer patients by germline BRCA1\/2 status in a large multicenter real-world database","volume":"152","author":"Mailliez","year":"2023","journal-title":"Int J Cancer"},{"key":"2026081005033030800_djag070-B24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnci\/djab151","article-title":"Association of genetic testing results with mortality among women with breast cancer or ovarian cancer","volume":"114","author":"Kurian","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2026081005033030800_djag070-B25","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026081005033030800_djag070-B26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026081005033030800_djag070-B27","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/bjc.2014.306","article-title":"Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy","volume":"111","author":"Kriege","year":"2014","journal-title":"Br J Cancer"},{"key":"2026081005033030800_djag070-B28","doi-asserted-by":"crossref","first-page":"e1229","DOI":"10.1016\/j.clbc.2017.12.014","article-title":"Impact of BRCA mutation status on survival of women with triple-negative breast cancer","volume":"18","author":"Yadav","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"2026081005033030800_djag070-B29","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.20.01200","article-title":"Mutations in BRCA1\/2 and other panel genes in patients with metastatic breast cancer -association with patient and disease characteristics and effect on prognosis","volume":"39","author":"Fasching","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026081005033030800_djag070-B30","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO-24-02442","article-title":"Breast, colorectal, and pancreatic cancer mortality with pathogenic variants in ATM, CHEK2, or PALB2","volume":"43","author":"Veenstra","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026081005033030800_djag070-B31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamaoncol.2022.5162","article-title":"Receipt of bilateral mastectomy among women with hereditary breast cancer","volume":"9","author":"Reid","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026081005033030800_djag070-B32","doi-asserted-by":"crossref","first-page":"e2449798","DOI":"10.1001\/jamanetworkopen.2024.49798","article-title":"West African genetic ancestry and breast cancer outcomes among black women","volume":"7","author":"Reid","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026081005033030800_djag070-B33","author":"Ai"},{"key":"2026081005033030800_djag070-B34","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"2026081005033030800_djag070-B35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40291-023-00650-5","article-title":"Validation of a transcriptome-based assay for classifying cancers of unknown primary origin","volume":"27","author":"Michuda","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"2026081005033030800_djag070-B36","author":"Ai"},{"key":"2026081005033030800_djag070-B37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026081005033030800_djag070-B38","doi-asserted-by":"crossref","first-page":"e2213070","DOI":"10.1001\/jamanetworkopen.2022.13070","article-title":"Prevalence of germline findings among tumors from cancer types lacking hereditary testing guidelines","volume":"5","author":"Yap","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026081005033030800_djag070-B39","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN guidelines\u00ae insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026081005033030800_djag070-B40","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41436-021-01171-4","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Miller","year":"2021","journal-title":"Genet Med"},{"key":"2026081005033030800_djag070-B41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2026081005033030800_djag070-B42","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.23.02614","article-title":"Neoadjuvant chemotherapy and immunotherapy for estrogen receptor-positive human epidermal growth factor 2-negative breast cancer","volume":"42","author":"Rios-Hoyo","year":"2024","journal-title":"JCO"},{"key":"2026081005033030800_djag070-B43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1200\/JCO.2023.41.16_suppl.521","article-title":"MammaPrint index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST","volume":"41","author":"Beitsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026081005033030800_djag070-B44","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"2026081005033030800_djag070-B45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41523-019-0109-7","article-title":"Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers","volume":"5","author":"Groenendijk","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"2026081005033030800_djag070-B46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41421-023-00614-3","article-title":"Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Discov"},{"key":"2026081005033030800_djag070-B47","doi-asserted-by":"crossref","first-page":"10086","DOI":"10.1038\/ncomms10086","article-title":"Patterns and functional implications of rare germline variants across 12 cancer types","volume":"6","author":"Lu","year":"2015","journal-title":"Nat Commun"},{"key":"2026081005033030800_djag070-B48","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1158\/1541-7786.MCR-19-1108","article-title":"Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer","volume":"18","author":"Park","year":"2020","journal-title":"Mol Cancer Res"},{"key":"2026081005033030800_djag070-B49","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1002\/cam4.4376","article-title":"TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer","volume":"10","author":"Grote","year":"2021","journal-title":"Cancer Med"},{"key":"2026081005033030800_djag070-B50","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa083","article-title":"Predicted chemotherapy benefit for breast cancer patients with germline pathogenic variants in cancer susceptibility genes","volume":"5","author":"Kurian","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"2026081005033030800_djag070-B51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41523-022-00426-w","article-title":"Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer","volume":"8","author":"Li","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2026081005033030800_djag070-B52","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III emerald trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026081005033030800_djag070-B53","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N Engl J Med"},{"key":"2026081005033030800_djag070-B54","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081005033030800_djag070-B55","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"2026081005033030800_djag070-B56","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40487-021-00162-4","article-title":"A real-world evidence study of CDK4\/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status","volume":"9","author":"Collins","year":"2021","journal-title":"Oncol Ther"},{"key":"2026081005033030800_djag070-B57","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.05.578934","article-title":"Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer","author":"Safonov","journal-title":"bioRxiv"},{"key":"2026081005033030800_djag070-B58","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","article-title":"Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials","volume":"34","author":"Andre","year":"2023","journal-title":"Ann Oncol"},{"key":"2026081005033030800_djag070-B59","doi-asserted-by":"crossref","first-page":"e2100140","DOI":"10.1200\/PO.21.00140","article-title":"Cyclin-dependent kinase 4\/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair-related genes","volume":"6","author":"Bruno","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"2026081005033030800_djag070-B60","doi-asserted-by":"crossref","first-page":"pkz027","DOI":"10.1093\/jncics\/pkz027","article-title":"The landscape of somatic genetic alterations in breast cancers from CHEK2 germline mutation carriers","volume":"3","author":"Mandelker","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"2026081005033030800_djag070-B61","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/jnci\/djy028","article-title":"The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers","volume":"110","author":"Weigelt","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2026081005033030800_djag070-B62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13058-023-01653-0","article-title":"Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile","volume":"25","author":"Smid","year":"2023","journal-title":"Breast Cancer Res"},{"key":"2026081005033030800_djag070-B63","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1038\/emboj.2009.294","article-title":"ATM activates p53 by regulating MDM2 oligomerization and E3 processivity","volume":"28","author":"Cheng","year":"2009","journal-title":"Embo J"},{"key":"2026081005033030800_djag070-B64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","article-title":"Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers","volume":"182","author":"Cragun","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2026081005033030800_djag070-B65","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/1078-0432.CCR-24-2058","article-title":"Germline-somatic interactions in BRCA-associated cancers: unique molecular profiles and clinical outcomes linking ATM to TP53 synthetic essentiality","volume":"31","author":"Arafa","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag070\/67360301\/djag070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/8\/1416\/67360301\/djag070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/8\/1416\/67360301\/djag070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:03:43Z","timestamp":1786352623000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/8\/1416\/8524333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":65,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,15]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag070","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,15]]}}}